Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by Citigroup

Vor Biopharma (NASDAQ:VOR) was upgraded by equities research analysts at Citigroup to a “strong-buy” rating in a research report issued on Thursday, Zacks reports.

Several other equities analysts have also recently commented on VOR. Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Wedbush raised their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Vor Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Vor Biopharma Stock Performance

VOR traded down $1.31 during midday trading on Thursday, reaching $18.03. The company’s stock had a trading volume of 733,078 shares, compared to its average volume of 1,316,671. The company has a fifty day simple moving average of $21.57 and a 200 day simple moving average of $18.37. Vor Biopharma has a twelve month low of $6.50 and a twelve month high of $31.31.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). On average, equities analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VOR. Braidwell LP grew its stake in Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after buying an additional 106,330 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Vor Biopharma in the first quarter valued at approximately $2,298,000. Bank of America Corp DE raised its stake in shares of Vor Biopharma by 28,408.1% in the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after acquiring an additional 112,496 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Vor Biopharma in the second quarter valued at approximately $1,799,000. Finally, Simplify Asset Management Inc. acquired a new position in shares of Vor Biopharma in the 1st quarter worth approximately $955,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.